Longevity Pharmaceuticals

SGLT2 Inhibitors (Empagliflozin)

Research / preclinical

Also known as: Jardiance, Farxiga

Diabetes drug with off-label longevity interest — cardiac, renal, metabolic benefits.

Open in AppAsk AI Advisor

Mechanism

SGLT2 inhibitor. Diabetes drug with off-label longevity interest — cardiac, renal, metabolic benefits. For full mechanism, dosing protocol, and stacking guidance, ask the AI Advisor or open the compound in-app.

Peer-Reviewed Studies (2)

Empagliflozin Cardiovascular Outcomes (EMPA-REG)

NEJM · 2015

38% reduction in CV death in T2D patients.

PubMed PMID 26378978 →

Empagliflozin Lifespan Extension in Mice (NIA ITP)

Aging Cell · 2024

Recent ITP data showed lifespan extension in male mice.

PubMed PMID 38924082 →

Related Compounds

Rapamycin

The only molecule shown to extend lifespan in every species tested — yeast to mammals.

Metformin

Most-prescribed diabetes drug, repurposed as the first FDA-approved aging trial.

Acarbose

Lifespan-extending diabetes drug — slows carb absorption, blunts post-meal glucose.

Low-Dose Naltrexone (LDN)

Off-label utility player — autoimmune modulation, pain reduction, HPA-axis support.

Telmisartan

ARB blood pressure med with PPARγ activity — investigational longevity application.

Doxycycline (low-dose)

MMP modulator at sub-antibiotic dose — connective tissue, periodontal support.